Hospital

The investigators found that population-based cancer registries showed a 10.2% decline in real-time electronic pathology reports in 2020 compared to 2019.

Lenacapavir was granted Breakthrough Therapy Designation in May 2019 and is a potential first-in-class capsid inhibitor for the treatment of HIV-1 infection without overlapping resistance with any currently approved antiretroviral therapy.

Umbralisib was granted accelerated approval by the FDA for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.

Treatments to stimulate the release of eggs increase estrogen hormone production and can act on breast cells, which has created concern that this could turn the cells cancerous.

Although it is the most common hospital-acquired infection, hospitals are not required to report non-ventilator-associated hospital-acquired pneumonia to the CDC National Healthcare Safety Network.

The use of high throughput technologies has revolutionized the understanding of the cancer genome.

Orelabrutinib is a highly selective Bruton's tyrosine kinase inhibitor designed to target B-cell lymphomas and autoimmune indications.

The DARE-19 clinical trial explores the use of SGLT2 inhibitors for patients with hypertension, cardiovascular disease, heart failure, type 2 diabetes, or chronic kidney disease, and COVID-19.

Investigators found that the therapeutic mechanism for bezlotoxumab, the only FDA-approved anti-TcdB antibody, is sensitive to escaping mutations in some bacterial strains.

Trilaciclib (Cosela) is indicated to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.

Initial data show that children presented with higher acuity in 2020 compared to the previous year.

The small-molecule inhibitors of the SOX 11 oncogene showed promise both as single agents and in combination with ibrutinib.

Azacitidine (Onureg) was approved by the FDA in September 2020 as a maintenance therapy for acute myeloid leukemia.

Panelists also recommended the use of bezlotoxumab as a co-intervention with standard of care antibiotics in patients with a recurrent C. diff infection within the past 6 months.

Ribociclib was found to prolong overall survival and improve post-progression outcomes in patients with HR-positive/HER2−negative advanced breast cancer, particularly among younger patients with a significant unmet need.

Results from the LOTIS-2 and LOTIS-3 trials show durable responses and a manageable toxicity profile among patients with both diffuse large B-cell lymphoma and mantle cell lymphoma treated with loncastuximab tesirine-lpyl (Zynlonta).

Community pharmacy teams can help reduce hospitalizations through the provision of medication reconciliation, which adjudicates discrepancies such as therapeutic omissions, duplications, dosing errors, drug interactions, and unintentional therapeutic changes.

The investigators said that although pneumococcal vaccines were known to reduce severe cases of childhood pneumonia, no studies from Asia had measured their efficacy until now.

According to the authors of the KEYNOTE-826 trial results, this is the first anti-programmed death receptor-1 (PD-1)/PD-L1 therapy to demonstrate improvements in OS and PFS that were clinically meaningful and statistically significant regardless of PD-L1 status.

Patients who received non-opioid prescriptions were more likely to report having no pain in the first week after surgery than those who received opioids and both groups reported equal levels of satisfaction.

Primary results from the randomized portion of the INVICTUS study had previously shown that ripretinib was able to significantly improve progression-free survival with a clinically meaningful overall survival benefit in patients with advanced gastrointestinal stromal tumor.

The FDA also approved dabigatran etexilate oral pellets for the prevention of recurrent clots in patients aged 3 months to less than 12 years of age who have completed treatment for their first venous thromboembolism.

Suzanne Soliman, PharmD, BCMAS, and Sally Arif, PharmD, BCPS, BCCP, discuss how the COVID-19 pandemic has impacted women in the pharmacy field.

In the ZUMA-5 cohort, 94% of patients achieved a response compared to 50% of patients in the control cohort with an odds ratio of 16.2.

Xembify (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease in patients 2 years of age and older.

Previous trials in non-hospitalized patients with COVID-19 suggested casirivimab and imdevimab reduced viral levels, shortened the time to resolution of symptoms and significantly reduced the risk of hospitalization or death.

Coordinating complex care plans can involve many care team members and even different pharmacists in both health system and retail environments.

The trial, in phase 3, is the first to report data comparing a neoadjuvant anti-HER2 based regimen with or without the anti-PD-L1 antibody, atezolimumab, in patients with high-risk, HER2-positive early breast cancer.

Pharmacists can educate patients about a pair of new treatment options for multiple myeloma approved by the FDA in March 2021.

These financial challenges can include difficulty paying medical bills or the inability to pay them at all, high financial distress, cost-related medication non-adherence, food insecurity, and delayed or foregone care due to cost.